Oral PDE4B Inhibitor Gets Breakthrough Tx Status for Idiopathic Pulmonary Fibrosis
BI 1015550 is an investigational oral phosphodiesterase 4B inhibitor with combined antifibrotic and anti-inflammatory effects.
BI 1015550 is an investigational oral phosphodiesterase 4B inhibitor with combined antifibrotic and anti-inflammatory effects.
Surgical lung biopsies that are performed via video-assisted thoracic surgery are safe for obtaining histopathologic tissue for select patients.
Early identification if interstitial lung disease (ILD), followed by subsequent tocilizumab therapy initiation, may preserve lung function in patients with systemic sclerosis-associated ILD.
Ziritaxestat is an investigational autotaxin inhibitor.
The sNDA includes data from a phase 2 trial that evaluated the efficacy and safety of pirfenidone in patients with progressive fibrosing UILD.
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
Treatment with nintedanib was associated with slowing the rate of forced vital capacity decline in patients with progressive fibrosing interstitial lung diseases.
In patients with sarcoidosis, cancer was found to develop earlier in men vs women.
In patients with idiopathic pulmonary fibrosis, treatment with pirfenidone was associated with a lower risk of mortality and acute respiratory-related hospitalizations than treatment with nintedanib.
There are significant differences in perceptions of prevalence, risk factors, and the management of RA-associated interstitial lung disease between rheumatologists and pulmonologists.